Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Filed by THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-15 06:26:11 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 23, 2025
Income
Not reported
Expenses
$100,000.00
Filing UUID
06c386b4-36c0-4009-9279-73d3ea0976bd
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB

BUD · Budget/Appropriations

Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions

GOV · Government Issues

Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs

MED · Medical/Disease Research/Clinical Labs

Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.